EP1987829A4 - Agent prophylactique ou therapeutique pour les lesions dues a l'ischemie cerebrale ou les lesions dues a l'ischemie cerebrale avec reperfusion dans l'accident vasculaire cerebral - Google Patents

Agent prophylactique ou therapeutique pour les lesions dues a l'ischemie cerebrale ou les lesions dues a l'ischemie cerebrale avec reperfusion dans l'accident vasculaire cerebral

Info

Publication number
EP1987829A4
EP1987829A4 EP07737295A EP07737295A EP1987829A4 EP 1987829 A4 EP1987829 A4 EP 1987829A4 EP 07737295 A EP07737295 A EP 07737295A EP 07737295 A EP07737295 A EP 07737295A EP 1987829 A4 EP1987829 A4 EP 1987829A4
Authority
EP
European Patent Office
Prior art keywords
cerebral
prophylactic
therapeutic agent
stroke
reperfusion injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07737295A
Other languages
German (de)
English (en)
Other versions
EP1987829A1 (fr
Inventor
Sookja Kim Chung
Stephen Chung
Chihiro Hibi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanwa Kagaku Kenkyusho Co Ltd
Original Assignee
Sanwa Kagaku Kenkyusho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co Ltd filed Critical Sanwa Kagaku Kenkyusho Co Ltd
Publication of EP1987829A1 publication Critical patent/EP1987829A1/fr
Publication of EP1987829A4 publication Critical patent/EP1987829A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La présente invention concerne un agent prophylactique ou thérapeutique pour les lésions induites par l'ischémie cérébrale ou les lésions induites par l'ischémie cérébrale avec reperfusion survenant dans le cadre d'un accident vasculaire cérébral tel qu'un infarctus cérébral ou une hémorragie cérébrale. L'efficacité de cet agent est basée sur un mécanisme différent de ceux des agents conventionnels et ledit agent peut être administré sur une période prolongée. L'agent prophylactique ou thérapeutique contient le principe actif 6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2- carboxamide. Le composé particulièrement préféré est le fidarestat, qui est une forme résolue optiquement et possédant une configuration (2S,4S).
EP07737295A 2006-02-20 2007-02-20 Agent prophylactique ou therapeutique pour les lesions dues a l'ischemie cerebrale ou les lesions dues a l'ischemie cerebrale avec reperfusion dans l'accident vasculaire cerebral Withdrawn EP1987829A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006041761 2006-02-20
PCT/JP2007/053036 WO2007097301A1 (fr) 2006-02-20 2007-02-20 Agent prophylactique ou therapeutique pour les lesions dues a l'ischemie cerebrale ou les lesions dues a l'ischemie cerebrale avec reperfusion dans l'accident vasculaire cerebral

Publications (2)

Publication Number Publication Date
EP1987829A1 EP1987829A1 (fr) 2008-11-05
EP1987829A4 true EP1987829A4 (fr) 2009-07-29

Family

ID=38437341

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07737295A Withdrawn EP1987829A4 (fr) 2006-02-20 2007-02-20 Agent prophylactique ou therapeutique pour les lesions dues a l'ischemie cerebrale ou les lesions dues a l'ischemie cerebrale avec reperfusion dans l'accident vasculaire cerebral

Country Status (8)

Country Link
US (1) US20090076105A1 (fr)
EP (1) EP1987829A4 (fr)
JP (1) JPWO2007097301A1 (fr)
KR (1) KR20080108465A (fr)
CN (1) CN101389332A (fr)
AU (1) AU2007218709A1 (fr)
CA (1) CA2642933A1 (fr)
WO (1) WO2007097301A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345378B1 (es) * 2009-03-20 2011-07-21 Consejo Superior De Investigaciones Científicas (Csic) Uso de un compuesto para la elaboracion de un medicamento destinado al tratamiento de una lesion producida por una reperfusion post-isquemica.
BR112012017071A2 (pt) 2010-01-14 2016-04-12 Univ Nagoya City produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular
WO2011136161A1 (fr) 2010-04-28 2011-11-03 株式会社 三和化学研究所 Médicament prophylactique ou thérapeutique pour des troubles de l'oreille interne
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CA2969857A1 (fr) * 2014-12-05 2016-06-09 Case Western Reserve University Compositions et procedes de modulation de s-nitrosylation
US11426386B2 (en) 2014-12-05 2022-08-30 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
CN111356764A (zh) 2017-09-25 2020-06-30 卡斯西部储备大学 降低血清胆固醇和pcsk9的组合物和方法
WO2020005938A1 (fr) 2018-06-25 2020-01-02 Case Western Reserve University Compositions et méthodes pour traiter une lésion tissulaire
WO2020061566A1 (fr) 2018-09-21 2020-03-26 Case Western Reserve University Inhibiteurs de l'aldocétoréductase et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
DE3769066D1 (de) * 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
JP2997894B2 (ja) * 1990-11-07 2000-01-11 株式会社三和化学研究所 循環器系疾患の予防及び治療剤
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
WO2002098462A1 (fr) * 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation
EP1683805A4 (fr) * 2003-10-24 2009-06-17 Meiji Seika Kaisha Nouvel inhibiteur de formation de produit terminal de glycation avancee et inhibiteur d'aldose reductase
ES2386094T3 (es) * 2004-01-30 2012-08-08 Sanwa Kagaku Kenkyusho Co., Ltd. Agente terapéutico para el edema macular diabético
US20070299119A1 (en) * 2004-02-20 2007-12-27 Sanwa Kagaku Kenkyusho Co., Ltd. Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy
WO2006090699A1 (fr) * 2005-02-22 2006-08-31 Sanwa Kagaku Kenkyusho Co., Ltd. Agent préventif ou thérapeutique pour dysfonction cardiaque ou dommage myocardique provoqué par ischémie ou reperfusion d’ischémie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2007097301A1 *

Also Published As

Publication number Publication date
KR20080108465A (ko) 2008-12-15
CN101389332A (zh) 2009-03-18
WO2007097301A1 (fr) 2007-08-30
CA2642933A1 (fr) 2007-08-30
JPWO2007097301A1 (ja) 2009-07-16
AU2007218709A1 (en) 2007-08-30
EP1987829A1 (fr) 2008-11-05
US20090076105A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
EP1987829A4 (fr) Agent prophylactique ou therapeutique pour les lesions dues a l'ischemie cerebrale ou les lesions dues a l'ischemie cerebrale avec reperfusion dans l'accident vasculaire cerebral
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
ZA200409862B (en) Benzofused heteroaryl derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
WO2006012642A3 (fr) Derives de pyrrole en tant qu'agents pharmaceutiques
WO2007044085A3 (fr) Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
AU2001257444A1 (en) Methods and compositions for enhancing cellular function through protection of tissue components
WO2006086447A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2001098236A3 (fr) Composes de tetracycline 7-phenyl-substituee
AU2000279625A1 (en) Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
WO2002102376A8 (fr) Composition pharmaceutique orale stabilisée
WO2008008397A3 (fr) Mousse pharmaceutique à base d'acide gras
AU2000279624A1 (en) Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
WO2010005480A3 (fr) Compositions à libération contrôlée d'agents qui réduisent les niveaux de plaquettes en circulation et procédés associés
MY137969A (en) Crystal form of asenapine maleate
WO2003044015A3 (fr) Acides heteroarylalkanoiques substitues
WO2007026024A3 (fr) Benzodiazepines en tant qu'inhibiteurs du vhc
WO2006116221A3 (fr) Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques
AU6169501A (en) Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
EP1619180A4 (fr) ANTAGONISTE DE CaSR
WO2007133751A3 (fr) Formulations de polyorthoester à base stabilisée
EP1886691A3 (fr) Formulation pharmaceutique comprenant un inhibiteur de la thrombine à faible masse moléculaire et son précurseur
WO2006125178A3 (fr) Composes de pyridazine tricycliques et leurs utilisations comme agents therapeutiques
WO2001000566A3 (fr) Acides phenoxyacetiques substitues
WO2002098850A3 (fr) Nouveaux composes et compositions utilises en tant qu'inhibiteurs de cathepsine
EP1262196A3 (fr) Combinaison d'un inhibiteur de la recapture de monoamines et d'un antagoniste opioique pour l'utilisation dans l'alcoolisme et la dépendance alcoolique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090629

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090929